All In Biotech

Drug Trial Radar · NCT04375436

Safety and Tolerability of NTRX-07 in Healthy Volunteers

NTRX 07-C101: A Phase 1, Randomized, Placebo-Controlled, Modified Parallel Design Single Ascending Dose Study of NTRX 07 to Assess Safety and Tolerability and Pharmacokinetics in Adult Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Nov 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Oct 10, 2019

Primary completion

May 15, 2020

Study completion Jun 30, 2020

Sponsor

Lead sponsor
NeuroTherapia, Inc.Industry
Sponsor type
Industry
Collaborators
Integrium; Orange County Research Center
First posted
May 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Randomized, placebo-controlled, modified parallel-design single ascending dose (SAD) in adult healthy volunteers (HVs).

Conditions

  • Pain, Neuropathic

Interventions

  • NTRX-07-SDDDrug

    NTRX-07-SDD for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with treatment emergent adverse events of NTRX-07Time frame: Seven days
  2. Number of subjects with Treatment related subjective effects of NTRX-07Time frame: Seven days
  3. Plasma levels of NTRX-07Time frame: 24 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Orange County Research Center

    Tustin, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.